Hikal Ltd Releases Annual Report for FY 2025-26

Hikal Ltd has released its Annual Report for the financial year 2025-26, along with the notice for its 38th Annual General Meeting (AGM). The report highlights the company's focus on innovation and sustainability, emphasizing advancements in its Pharmaceuticals, Crop Protection, and Animal Health businesses. Key developments include strengthening the CDMO pipeline, operationalizing a High-Potency API (HPAPI) laboratory, and commissioning a Kilo Lab to accelerate scale-up. The company also reinforced quality, compliance, and manufacturing excellence while embedding sustainability across operations. The report details strategic reviews, financial performance, risk management, and ESG initiatives, underscoring Hikal's commitment to creating long-term value for stakeholders.